| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
4 analysts have shared their evaluations of Harmony Biosciences (NASDAQ:HRMY) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 0 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 3 | 0 | 0 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
Analysts have set 12-month price targets for Harmony Biosciences, revealing an average target of $51.0, a high estimate of $52.00, and a low estimate of $48.00. Highlighting a 1.92% decrease, the current average has fallen from the previous average price target of $52.00.
The standing of Harmony Biosciences among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Ami Fadia | Needham | Maintains | Buy | $52.00 | $52.00 |
| Ami Fadia | Needham | Maintains | Buy | $52.00 | $52.00 |
| Ami Fadia | Needham | Maintains | Buy | $52.00 | $52.00 |
| David Hoang | Citigroup | Announces | Buy | $48.00 | - |
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Harmony Biosciences's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on Harmony Biosciences analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant), is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and used for the treatment of cataplexy in adult patients with narcolepsy.
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Harmony Biosciences's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 29.79% as of 31 March, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Harmony Biosciences's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 24.79% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Harmony Biosciences's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 7.8% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 4.62%, the company showcases effective utilization of assets.
Debt Management: Harmony Biosciences's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.37.
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: HRMY
